MA28121A1 - Agent immunothérapique utile pour le traitement combiné de la tuberculose en association avec d'autres médicaments - Google Patents

Agent immunothérapique utile pour le traitement combiné de la tuberculose en association avec d'autres médicaments

Info

Publication number
MA28121A1
MA28121A1 MA28985A MA28985A MA28121A1 MA 28121 A1 MA28121 A1 MA 28121A1 MA 28985 A MA28985 A MA 28985A MA 28985 A MA28985 A MA 28985A MA 28121 A1 MA28121 A1 MA 28121A1
Authority
MA
Morocco
Prior art keywords
tuberculosis
drugs
combination
combined treatment
immunotherapeutic agent
Prior art date
Application number
MA28985A
Other languages
English (en)
Inventor
Iglesias Pere Joan Cardona
Riera Isabel Mata
Original Assignee
Archivel Farma Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Archivel Farma Sl filed Critical Archivel Farma Sl
Publication of MA28121A1 publication Critical patent/MA28121A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne un agent immunothérapique basé sur des fragments de paroi cellulaire d'une souche virulente de Mycobacterium tuberculosis, à un procédé pour l'obtenir, à des formulations pharmaceutiques qui le contiennent et à son usage pour la préparation d'un médicament pour le traitement combiné de la tuberculose en association avec d'autres médicaments.
MA28985A 2003-10-31 2006-04-28 Agent immunothérapique utile pour le traitement combiné de la tuberculose en association avec d'autres médicaments MA28121A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200302551A ES2231037B1 (es) 2003-10-31 2003-10-31 Agente inmunoterapico util para el tratamiento combinado de la tuberculosis en asociacion con otros farmacos.

Publications (1)

Publication Number Publication Date
MA28121A1 true MA28121A1 (fr) 2006-08-01

Family

ID=34530979

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28985A MA28121A1 (fr) 2003-10-31 2006-04-28 Agent immunothérapique utile pour le traitement combiné de la tuberculose en association avec d'autres médicaments

Country Status (20)

Country Link
US (1) US8246944B2 (fr)
EP (1) EP1690549B1 (fr)
JP (1) JP4998988B2 (fr)
KR (1) KR101146469B1 (fr)
CN (1) CN100490894C (fr)
AT (1) ATE428442T1 (fr)
AU (1) AU2004285305B2 (fr)
BR (1) BRPI0415695B8 (fr)
CA (1) CA2543659C (fr)
DE (1) DE602004020663D1 (fr)
DK (1) DK1690549T3 (fr)
ES (2) ES2231037B1 (fr)
IL (1) IL175030A (fr)
MA (1) MA28121A1 (fr)
NZ (1) NZ546715A (fr)
PL (1) PL1690549T3 (fr)
PT (1) PT1690549E (fr)
RU (1) RU2341287C2 (fr)
WO (1) WO2005042013A1 (fr)
ZA (1) ZA200604234B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2231037B1 (es) 2003-10-31 2005-12-16 Archivel Technologies, Sl Agente inmunoterapico util para el tratamiento combinado de la tuberculosis en asociacion con otros farmacos.
US20100166840A1 (en) * 2006-05-12 2010-07-01 Japan Bcg Laboratory Liposome having lipid membrane containing bacterial cell component
ES2307402B1 (es) * 2006-10-30 2009-09-30 Archivel Farma, S.L. Vacuna profilactica contra la tuberculosis.
ES2335177B1 (es) * 2008-09-19 2011-02-28 Archivel Farma, S.L. Agente inmunoterapeutico apropiado para la profilaxis primaria de la tuberculosis.
EP2471511A1 (fr) 2011-01-04 2012-07-04 Archivel Farma, SL Formulation de liposome adaptée pour le traitement ou la prévention de la tuberculose
WO2012093137A1 (fr) * 2011-01-04 2012-07-12 Archivel Farma, Sl Formulation de liposomes adaptée au traitement ou à la prévention de la tuberculose
PL2802345T3 (pl) 2012-01-12 2018-08-31 Archivel Farma, S.L. Szczepionka mtb-c przeciw reakcjom alergicznym
ES2758400B2 (es) 2018-11-02 2021-01-20 Univ Granada Nanoparticulas biomimeticas mediadas por mamc
WO2023062066A1 (fr) 2021-10-14 2023-04-20 Archivel Farma, S.L. Formulations de liposomes pour le traitement de la tuberculose active
WO2025191183A1 (fr) 2024-03-15 2025-09-18 Archivel Farma S.L. Formulations de liposomes pour le traitement du cancer

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3125598A1 (de) * 1981-06-30 1983-01-13 Mahle Gmbh, 7000 Stuttgart Einrichtung zur druckbeaufschlagung des presszylinders einer druckgiessmaschine
JPS59161320A (ja) * 1983-03-04 1984-09-12 Maruyama Chisato リポ多糖体およびその製造法
GB8404280D0 (en) * 1984-02-17 1984-03-21 Stanford J L Biological preparations
JPS624701A (ja) * 1985-06-29 1987-01-10 Maruyama Chisato リポ多糖体及びその製造法
US4744984A (en) * 1985-10-08 1988-05-17 Vetrepharm Research, Inc. Antiviral immunotherapeutic agent and preparation thereof
US5542935A (en) * 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
US6641814B1 (en) * 1997-04-02 2003-11-04 Statens Serum Institut Nucleic acids fragments and polypeptide fragments derived from M. tuberculosis
US5785975A (en) * 1995-06-26 1998-07-28 Research Triangle Pharmaceuticals Adjuvant compositions and vaccine formulations comprising same
US6284255B1 (en) * 1996-08-29 2001-09-04 Genesis Research & Development Corporation Limited Compounds and methods for treatment and diagnosis of mycobacterial infections
US6982085B2 (en) * 1997-04-02 2006-01-03 Statens Serum Institut TB diagnostic based on antigens from M. tuberculosis
EP1117683A2 (fr) * 1998-10-08 2001-07-25 Statens Serum Institut Vaccin et diagnostic tb selon les antigenes de la cellule du bacille de koch
RU2153354C1 (ru) * 1999-03-31 2000-07-27 Московский городской научно-практический центр борьбы с туберкулезом Вакцина против туберкулеза
WO2002045736A1 (fr) * 2000-12-08 2002-06-13 The Johns Hopkins University Methodes permettant d'ameliorer le diagnostic et le traitement d'infections mycobacteriennes
EP1360498B1 (fr) * 2001-01-08 2009-10-14 The Government of the United States of America, as represented by the Secretary, Department of Health & Human Services Antigene diagnostique pour la tuberculose humaine latente et methode d'utilisation associee
AU2002254206A1 (en) * 2001-03-16 2002-10-03 Sarawak Medichem Pharmaceuticals, Inc. Pyranocoumarin compounds as a novel pharmacophore with anti-tb activity
EP2196473A1 (fr) 2001-07-04 2010-06-16 Health Protection Agency Antigènes mycobacteriens exprimes pendant la phase de latence
WO2003018053A1 (fr) 2001-08-22 2003-03-06 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Vaccin contre des pathologies induites par mycobacteries
EP1478391A1 (fr) 2002-01-29 2004-11-24 Bakulesh Mafatlal Khamar Procede relatif a la prophylaxie de la tuberculose chez des sujets porteurs du vih
ES2231037B1 (es) 2003-10-31 2005-12-16 Archivel Technologies, Sl Agente inmunoterapico util para el tratamiento combinado de la tuberculosis en asociacion con otros farmacos.
DE102004053141A1 (de) * 2004-11-03 2006-05-04 Schülke & Mayr GmbH Desinfektionsmittel mit verbesserter Wirksamkeit gegen Mykobakterien

Also Published As

Publication number Publication date
CN1874785A (zh) 2006-12-06
ZA200604234B (en) 2007-11-28
CA2543659A1 (fr) 2005-05-12
IL175030A (en) 2012-02-29
CN100490894C (zh) 2009-05-27
JP2007509910A (ja) 2007-04-19
US8246944B2 (en) 2012-08-21
ATE428442T1 (de) 2009-05-15
HK1098362A1 (zh) 2007-07-20
PL1690549T3 (pl) 2010-01-29
BRPI0415695B1 (pt) 2019-09-10
US20070269501A1 (en) 2007-11-22
AU2004285305B2 (en) 2009-11-12
ES2231037B1 (es) 2005-12-16
DE602004020663D1 (de) 2009-05-28
EP1690549B1 (fr) 2009-04-15
DK1690549T3 (da) 2009-08-17
IL175030A0 (en) 2006-08-20
RU2341287C2 (ru) 2008-12-20
EP1690549A1 (fr) 2006-08-16
ES2231037A1 (es) 2005-05-01
JP4998988B2 (ja) 2012-08-15
RU2006118795A (ru) 2007-12-10
PT1690549E (pt) 2009-07-20
CA2543659C (fr) 2012-04-17
NZ546715A (en) 2008-05-30
KR101146469B1 (ko) 2012-05-21
AU2004285305A1 (en) 2005-05-12
BRPI0415695A (pt) 2006-12-26
KR20060126963A (ko) 2006-12-11
ES2325835T3 (es) 2009-09-21
WO2005042013A1 (fr) 2005-05-12
BRPI0415695A8 (pt) 2019-01-15
BRPI0415695B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
EP1790340A3 (fr) Chimotherapie combinée
MA28121A1 (fr) Agent immunothérapique utile pour le traitement combiné de la tuberculose en association avec d'autres médicaments
MA29378B1 (fr) Composition pharmaceutique comprenant une diphenyluree substituee par un omega-carboxyaryle pour le traitement du cancer
MA28182A1 (fr) Analogues d'oligonucleotides de classe c presentant des proprietes immunostimulatrices accrues
MA29871B1 (fr) Composition pharmaceutique concue pour ameliorer la fonction cognitive
TR200101895T2 (tr) Cinsel rahatsızlıkların tedavisi.
TW200633730A (en) Oral disintegrating dosage forms
IL151388A (en) Use of il-18 inhibitors
WO2001092283A3 (fr) Composes de cobalamine utilises en tant qu'agents cardio-vasculaires et agents d'imagerie
EP1827409A4 (fr) Compositions de rasagiline delitantes oralement
DK1383752T3 (da) Deutererede 3-piperidinopropiophenoner samt lægemidler indeholdende disse forbindelser
MA29278B1 (fr) Composition pharmaceutique comprenant un derive de l'indolylmaleimide
GB2431346C (en) A combination composition comprising paracetamol and ibuprofen
WO2004014367A3 (fr) Immunisation anti-amyloide et inhibiteurs de cox-2 utilises dans le traitement de la maladie d'alzheimer
MY134019A (en) Aryl oxime-piperazines useful as ccr5 antagonists
MA27150A1 (fr) Associations pharmaceutiques d'un agoniste de recepteur d'adenosine a2a et d'un agoniste de recepteur adrenergique beta-2
Manos et al. Discontinuing antiparkinson medication in chronic schizophrenics: At what cost to the patient?
HUP0401940A2 (hu) Diabetikus neuropátia esetében alkalmazható gyógyszerkészítmény
Mühlbacher et al. Intravenous mirtazapine is safe and effective in the treatment of depressed inpatients
MA29813B1 (fr) Combinaisons pharmaceutiques contenant de la lamivudine, de la stavudine et de la nevirapine
TR200301552A1 (tr) Rofekoksib' in yeni oral farmakolojik formülasyonları.
TR200502061T2 (tr) IL-18 inhibitörlerinin kullanımı.
AU2001295839A1 (en) Use of agents active against candida in the treatment of disorders of the oral and intestinal mucosa
UA85069C2 (ru) Комбинационная медикаментозная терапия в лечении ожирения
ECSP972162A (es) Formas solidas de dosificacion oral que contienen valsartan